Section Arrow
Quote
IKT.NASDAQ
- Inhibikase Therapeutics
Quotes are at least 15-min delayed:2025/06/04 15:24 EDT
Last
 2.01
-0.02 (-0.99%)
Day High 
2.05 
Prev. Close
2.03 
1-M High
2.3 
Volume 
74.43K 
Bid
2
Ask
2.02
Day Low
1.99 
Open
2.03 
1-M Low
1.7 
Market Cap 
150.91M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.96 
20-SMA 1.99 
50-SMA 2.05 
52-W High 4.2 
52-W Low 1.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.58/-0.52
Enterprise Value
150.91M
Balance Sheet
Book Value Per Share
1.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLRBCellectar Biosciences0.4915+0.2139+77.05%-- 
NCNANuCana plc0.0449-0.0149-24.92%-- 
RXRXRecursion Pharmaceuticals4.88+0.49+11.16%-- 
HOTHHoth Therapeutics1.51+0.5902+64.17%-- 
SGMTSagimet Biosciences4.185+0.555+15.29%-- 
Quotes are at least 15-min delayed：2025/06/04 15:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.